Rapid characterization of the major drug-metabolizing human hepatic cytochrome P-450 enzymes expressed in Escherichia coli

Drug Metabolism and Disposition

Volumn 27, Issue 9, 1999, Pages 1017-1023

  McGinnity, Dermot F ^a   Griffin, Sarah J ^a   Moody, Graeme C ^a   Voice, Mike ^b   Hanlon, Stephen ^b   Friedberg, Thomas ^b   Riley, Robert J ^a  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DEXTROMETHORPHAN; DIAZEPAM; DRUG METABOLIZING ENZYME; ERYTHROMYCIN; ETHOXYRESORUFIN; NAPROXEN; RECOMBINANT ENZYME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE;

ARTICLE; B LYMPHOBLAST; DEALKYLATION; ESCHERICHIA COLI; HUMAN; HUMAN CELL; KINETICS; LIVER MICROSOME; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CYTOCHROME P-450 ENZYME SYSTEM; ESCHERICHIA COLI; HUMANS; ISOENZYMES; KINETICS; LIVER; PHARMACEUTICAL PREPARATIONS; PLASMIDS; PREDICTIVE VALUE OF TESTS; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY;

ESCHERICHIA COLI;

EID: 0032841647     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Ahmad SR and Wolfe SM (1995) Cisapride and torsades de pointes. Lancet 345:508.
2. Andersson T, Miners JO, Veronese ME and Birkett DJ (1994) Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol 38:131-137.
3. Aoyama T, Korzekwa K, Nagata K, Gillette J, Gelboin HV and Gonzalez FJ (1990) Estradiol metabolism by complementary deoxyribonucleic acid-expressed human cytochrome P450s. Endocrinology 124:3101-3106.
4. Becquemont L, Le Bot MA, Riche C, Funck-Brentano C, Jaillon P and Beaune P (1998) Use of heterologously expressed human cytochrome P450 1A2 to predict tacrine-fluvoxamine drug interaction in man. Pharmacogenetics 8:101-108.
5. Blake JAA, Pritchard M, Ding S, Smith GCM, Burchell B, Wolf CR and Friedberg T (1996) Coexpression of a human P450 (CYP3A4) and P450 reductase generates a highly functional monooxygenase system in Escherichia coli. FEBS Lett 397:210-214.
6. m catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics 7:211-221.
7. Ching MS, Blake CL, Ghabrial H, Wynne Ellis S, Lennard MS, Tucker GT and Smallwood R (1995) A potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites. Biochem Pharmacol 50:833-837.
8. Clarke SE, Ayrton JC and Chenery RJ (1994) Characterization of the inhibition of P4501 A2 by furafylline. Xenobiotica 24:517-526.
9. Cook CS, Hauswald C, Oppermann JA and Schoenhard GL (1993) Involvement of cytochrome P4503A in the metabolism of potassium canrenoate to an epoxide: Mechanism of inhibition of the epoxide formation by spiranalactone and its sulfur-containing metabolite. J Pharmacol Exp Ther 266:1-7.
10. Crespi CL and Miller VP (1997) The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics 7:203-210.
11. Crespi CL, Miller VP and Penman BW (1997) Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem 248:188-190.
12. Crespi CL and Penman BW (1997) Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug-interactions. Adv Pharmacol 43:171-188.
13. Eugster HP, Probst M, Wurgler FE and Sengstag S (1993) Caffeine, estradiol and progesterone interact with human CYP1A1 and CYP1A2. Drug Metab Dispos 21:43-49.
14. Fisher CW, Caudle DL, Martin-Wixtron C, Quattrochi LC, Tukey RH, Waterman MR and Estabrook RW (1992) High level expression of functional human cytochrome P450 1A2 in Escherichia coli. FASEB J 6:759-764.
15. Gonzalez FJ and Korzekwa KR (1995) Cytochrome P450 expression systems. Annu Rev Pharmacol Toxicol 35:369-390.
16. Gorski JC, Jones DR, Wrighton SA and Hall SD (1994) Characterisation of dextromethorphan N-demethylation by human liver microsomes: Contribution of the cytochrome P450 3A subfamily. Biochem Pharmacol 48:173-182.
17. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC and Cantilena LR (1993) Terfenadine-ketoconazole interaction: Pharmacokinetic and electrocardiographic consequences. JAMA 269:1513-1518.
18. Ingelman-Sundberg M, Hagbjork A-L, Ueng Y-F, Yamazaki H and Guengerich FP (1996) High rates of substrate hydroxylation by human cytochrome P450 3A4 in reconstituted membranous vesicles: Influence of membrane charge. Biochem Biophys Res Commun 221:318-322.
19. Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP and Shimada T (1997) Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics 7:103-113.
20. Iwata H, Fujita K, Kushida H, Suzuki A, Konno Y, Makamura K, Fujino A and Kamataki T (1998) High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli. Biochem Pharmacol 55:1315-1325.
21. Jacqz-Aigrain E, Funck-Brentano C and Cresteil T (1993) CYP2D6 and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 3:197-204.
22. m diazeparn N-demethylases. Drug Metab Dispos 25:133-139.
23. Kerry NL, Somogyi AA, Bochner F and Mikus G (1994) The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: In vitro studies using human liver microsomes. Br J Clin Pharmacol 38:243-248.
24. Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez FJ and Tracy TS (1998) Evaluation of atypical cytochrome P450 kinetics with two-substrate models: Evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37:4137-4147.
25. Kroemor HK and Eichelbaum M (1995) 'It's the genes, stupid'. Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 56:2285-2298.
26. 2-terminal segment retains catalytic activity and is membrane-bound when expressed in Escherichia coli. J Biol Chem 266:7321-7324.
27. Maenpaa J, Hall SD, Ring BJ, Strom SC and Wrighton SA (1998) Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: The effect of assay conditions and regioselective stimulation by α-napthoflavone, terfenadine and testosterone. Pharmacogenetics 8:137-155.
28. Mahgoub A, Idle JR, Dring LG, Lancaster R and Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2:584-586.
29. Miners JO, Coulter S, Tukey RH, Veronese ME and Birkett DJ (1996) Cytochromes P450, 1A2 and 2C9 are responsible for the human hepatic O-demethylation of R-and S-naproxen. Biochem Pharmacol 51:1003-1008.
30. Moody GC, Griffin SJ, Mather AN, McGinnity DF and Riley RJ (1999) Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: Assessment of human CYP inhibition potential. Xenobiotica 29:53-75.
31. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
32. Ono S, Hatanaka T, Miyazawa S, Tsutsui M, Aoyama T, Gonzalez FJ and Satoh T (1996) Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: Role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica 24:1155-1166.
33. Parkinson A (1996) An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol Pathol 24:45-57.
34. Pastrakuljic A, Tang BK, Roberts EA and Kalow W (1997) Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. Biochem Pharmacol 53: 531-538.
35. Pritchard MP, Ossetian R, Li DN, Henderson CJ, Burchell B, Wolf CR and Friedberg T (1997) A general strategy for the expression of recombinant human cytochrome P450s in Escherichia coli using bacterial signal peptides: Expression of CYP3A4, CYP2A6 and CYP2E1. Arch Biochem Biophys 345:342-354.
36. Pritchard PM, Glancey MJ, Blake JAR, Gilham DE, Burchell B, Wolf CR and Friedberg T (1998) Functional co-expression of CYP2D6 and human NADPH-cytochrome P450 reductase in Escherichia coli. Pharmacogenetics 8:33-42.
37. Remmel RP and Burchell B (1993) Validation and use of cloned, expressed human drug-metabolizing enzymes in heterologous cells for analysis of drug metabolism and drug-drug interactions. Biochem Pharmacol 46:559-566.
38. Richardson T, Jung F, Griffin KJ, Wester M, Raucy JL, Kemper B, Bornheim LM, Hassett C, Omiecinski CJ and Johnson EF (1995) A universal approach to the expression of human and rabbit cytochrome P450s of the 2C subfamily of Escherichia coli. Arch Biochem Biophys 323:87-96.
39. 14C]erythromycin. J Pharmacol Toxicol Methods 38:189-193.
40. Riley RJ, Lambert C, Cooper AE, Richmond H, Hall M, Jordan MC, Logan CJ and Clark B (1995) Induction of rodent hepatic drug-metabolizing enzyme activities by the novel anticonvulsant remacemide hydrochloride. Drug Metab Dispos 23:922-928.
41. 14C] naproxen O-demethylase activity in human liver microsomes: Evidence for the involvement of cytochrome P4501A2 and P4502C9/10. Drug Metab Dispos 24:126-136.
42. 14C] dextromethorphan. Anal Biochem 219:309-320.
43. Sandhu P, Baba T and Guengerich FP (1993) Expression of modified cytochrome P450 2C10 (2C9) in Escherichia coli, purification and reconstitution of catalytic activity. Arch Biochem Biophys 306:443-450.
44. Schmider J, Greenblatt DJ, Fogelman SM, von Moltke LL and Shader RI (1997) Metabolism of dextromethorphan in vitro: Involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1. Biopharm Drug Dispos 18:227-240.
45. Shet MS, Fisher CW, Holmans PL and Estabrook RW (1993) Human cytochrome P450 3A4: Enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase. Proc Natl Acad Sci USA 90:11748-11752.
46. Shimada T, Yamazaki H, Mimura M, Yukiharu I and Guengerich FP (1994) Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
47. Tassaneeyakul W, Mohamed Z, Birkett DJ, McManus ME, Veronese ME, Tukey RH, Quattrochi LC, Gonzalez FJ and Miners JO (1992) Caffeine as a probe for human cytochromes P450: Validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetics 2:173-183.
48. Tracy TS, Marra C, Wrighton SA, Gonzalez FJ and Korzekwa KR (1997) Involvement of multiple cytochrome P450s in naproxen O-demethylation. Eur J Clin Pharmacol 52:293-298.
49. Venkatakrishnan K, von Moltke LL and Greenblatt DJ (1998) Relative quantities of catalytically active CYP2C9 and 2C19 in human liver microsomes: Application of the relative activity factor approach. J Pharm Sci 87:845-853.
50. Wang RW, Newton DJ, Scheri TD and Lu AYH (1997) Human cytochrome P4503A4-catalysed testosterone 6β-hydroxylation and erythromycin N-demethylation: Competition during catalysis. Drug Metab Dispos 25:502-507.
51. Watanabe N, Kamei S, Ohkubo A, Yamanaka M, Ohsawa S, Makino K and Tokuda K (1986) Urinary protein as measured with a pyrogallol red-molybdate complex, manually and in a Hitachi 726 automated analyzer. Clin Chem 32:1551-1554.
52. Waterman MR (1993) Heterologous expression of cytochrome P-450 in Escherichia coli. Biochem Soc Trans 21:1081-1085.
53. Waterman MR, Jenkins CM and Pikuleva I (1995) Genetically engineered bacterial cells and applications. Toxicol Lett 82-83:807-813.
54. Williams FM, Mutch E, Woodhouse KW, Lambert D and Rawlins MD (1986) Ethoxyresorufin O-deethylation by human liver microsomes. Br J Clin Pharmacol 22:263-268.
55. Yamazaki H, Ueng Y-F, Shimada T and Guengerich FP (1995) Roles of divalent metal ions in oxidations catalyzed by recombinant cytochrome P450 3A4 and replacement of NADPH-cytochrome P450 reductase with other flavoproteins, ferredoxin, and oxygen surrogates. Biochemistry 34:8380-8939.
56. Yasumori T, Nagata K, Yang SK, Chen L-S, Murayama N, Yamazoe Y and Kato R (1993) Cytochrome P450 mediated metabolism of diazepam in human and rat: Involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner. Pharmacogenetics 3:291-301.
57. Zomorodi K and Houston JB (1996) Diazepam-omeprazole inhibition interaction: An in vitro investigation using human liver microsomes. Br J Clin Pharmacol 42:157-162.